Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Multiple Myeloma 55Recurrence 7Lymphoma 6Neoplasms, Plasma Cell 5Immunoglobulin Light-chain Amyloidosis 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Paraproteinemias 2Neoplasms 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Leukemia, Myeloid, Acute 2beta-Thalassemia 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thalassemia 1Sarcoma, Myeloid 1Prostatic Neoplasms 1Plasmablastic Lymphoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphadenopathy 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Lenalidomide 6Dexamethasone 6Cyclophosphamide 5Bortezomib 5fludarabine 3carfilzomib 3belantamab mafodotin 3pomalidomide 2fludarabine phosphate 2Melphalan 2Etoposide 2pembrolizumab 1isatuximab 1elotuzumab 1daratumumab 1Whole-Body Irradiation 1Thalidomide 1Tacrolimus 1Sirolimus 1Resistance Training 1Radiotherapy 1Pharmaceutical Preparations 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1Mycophenolic Acid 1Methotrexate 1Exercise 1Equipment and Supplies 1Doxorubicin 1Cyclosporine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × Bortezomib × 90 days × Clear all
NCT06152575 2026-06-05

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Pfizer

Phase 3 Recruiting
492 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07600151 2026-05-20

CONQUISTADOR

Universitätsklinikum Hamburg-Eppendorf

Phase 1/2 Not yet recruiting
220 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00871013 2026-05-11

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

University of Arkansas

Phase 2 Active not recruiting
160 enrolled
Plasma cell

Neoplasms, Plasma Cell

NCT03984097 2026-04-09

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Takeda

Phase 1 Completed
50 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01191060 2026-04-06

IFM/DFCI2009

University Hospital, Toulouse

Phase 3 Completed
700 enrolled
Plasma cell

Disease Progression, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡